|Date d'ouverture :||12/08/2021|
|Date clôture :||31/08/2028|
|Promoteur :||ALX Oncology Inc.|
|Progression du cancer:||Loco-régional et à distance|
This is a randomized phase 2 (open-label) / 3 (double-blind), international, multi-center study of patients with metastatic HER2-overexpressing gastric/GEJ adenocarcinoma that has progressed on or after prior HER2-directed therapy and fluoropyrimidine- or platinum-containing chemotherapy and are suitable for chemotherapy (2nd-line or 3rd-line). Approximately 450 adult patients are expected to be enrolled in the study across both phases.